Monitor outcome of the FDA meeting as it will determine whether the BLA for ONS-5010/LYTENAVA will be approved, which is critical for this small-cap biotech's future revenue potential.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $0.2500entry
- T+1 · 7mo ago −11.20%α −11.78% · $0.2220
- T+5 · 7mo ago +9.20%α +5.66% · $0.2730
- T+20 · 7mo ago −7.20%α −15.75% · $0.2320
- T+60 · 4mo ago +468.00%α +456.58% · $1.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Outlook Therapeutics submitted a formal dispute resolution request to the FDA regarding a Complete Response Letter for its ONS-5010/LYTENAVA biologics license application, and the FDA has accepted the request and granted a meeting with the deciding official. This is a procedural step in the regulatory review process for a drug that was previously not approved.
Key Facts
- Company submitted a Formal Dispute Resolution Request (FDRR) to the FDA regarding a December 30, 2025 Complete Response Letter (CRL) for ONS-5010/LYTENAVA
- FDA accepted the FDRR and granted a meeting with the deciding official to be conducted in April 2026
- The BLA concerns ONS-5010/LYTENAVA for treatment of neovascular age-related macular degeneration
- Company believes existing clinical data from NORSE TWO and NORSE EIGHT trials support approval
Financial Impact
No immediate financial impact disclosed; outcome of FDA dispute resolution will determine future commercial potential
Risk Factors
- FDA may uphold its Complete Response Letter and deny approval
- Further delays or requests for additional clinical data could increase development costs
- Competitive risks if rival treatments gain market share during approval delay
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-040387 |
| Document: tm2611268d1_ex99-1.htm | 0001104659-26-040387 |
| Document: 0001104659-26-040387-index-headers.html | 0001104659-26-040387 |
| Document: 0001104659-26-040387-index.html | 0001104659-26-040387 |
| Document: 0001104659-26-040387.txt | 0001104659-26-040387 |
Track record
37 reports on OTLK
13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers